Everolimus
Sign in to save this workspacePrimary targets: FKBP12, MTOR_FRAP1 · FDA status: FDA Approved
Selectivity scorecard
KISS
100.00
Gini
0.706
CATDS
0.024
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Everolimus. Strongest target: PKMYT1 at 33.8% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | PKMYT1 | 33.8% | 66.2% |
| 2 | CAMKK2 | 28.8% | 71.2% |
| 3 | PDK2_PDHK2 | 28.6% | 71.4% |
| 4 | ERN1_IRE1 | 25.3% | 74.7% |
| 5 | STK33 | 22.2% | 77.8% |
| 6 | ALK2_ACVR1 | 21.6% | 78.4% |
| 7 | GSK3A | 21.5% | 78.5% |
| 8 | MLK3_MAP3K11 | 21.1% | 78.9% |
| 9 | MUSK | 19.4% | 80.6% |
| 10 | EGFR | 17.8% | 82.2% |
| 11 | WEE1 | 17.6% | 82.4% |
| 12 | CK1D | 17.5% | 82.5% |
| 13 | TRPM7_CHAK1 | 16.7% | 83.3% |
| 14 | CTK_MATK | 16.4% | 83.6% |
| 15 | NEK8 | 16.4% | 83.6% |
| 16 | ABL1 | 16.0% | 84.0% |
| 17 | TESK1 | 15.8% | 84.2% |
| 18 | TTBK2 | 15.6% | 84.4% |
| 19 | ROS_ROS1 | 15.6% | 84.4% |
| 20 | PHKG1 | 15.6% | 84.4% |
Selectivity landscape
Where Everolimus sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Everolimus.
Annotations
Sign in to read and post annotations.
Loading…